{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:33:55Z","timestamp":1790289235059,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background. \u2003The effectiveness of piperacillin-tazobactam (PTZ) for the treatment of extended-spectrum \u03b2-lactamase (ESBL) bacteremia is controversial. We compared 14-day mortality of PTZ vs carbapenems as empiric therapy in a cohort of patients with ESBL bacteremia who all received definitive therapy with a carbapenem.<\/jats:p>\n               <jats:p>Methods. \u2003Patients hospitalized between January 2007 and April 2014 with monomicrobial ESBL bacteremia were included. A decrease of &amp;gt;3 doubling dilutions in the minimum inhibitory concentration for third-generation cephalosporins tested in combination with 4 \u00b5g\/mL of clavulanic acid was used to confirm ESBL status. The primary exposure was empiric therapy, defined as antibiotic therapy administered to a patient before ESBL status was known. Patients were excluded if they did not receive a carbapenem after ESBL production was identified. The primary outcome was time to death from the first day of bacteremia. Propensity scores using inverse probability of exposure weighting (IPW) were used to estimate the probability that a patient would receive PTZ vs carbapenems empirically. We calculated overall hazard ratios for mortality censored at 14 days using Cox proportional hazards models on an IPW-adjusted cohort.<\/jats:p>\n               <jats:p>Results. \u2003A total of 331 unique patients with ESBL bacteremia were identified. One hundred three (48%) patients received PTZ empirically and 110 (52%) received carbapenems empirically. The adjusted risk of death was 1.92 times higher for patients receiving empiric PTZ compared with empiric carbapenem therapy (95% confidence interval, 1.07\u20133.45).<\/jats:p>\n               <jats:p>Conclusions. \u2003PTZ appears inferior to carbapenems for the treatment of ESBL bacteremia. For patients at high risk of invasive ESBL infections, early carbapenem therapy should be considered. Our findings should not be extended to \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in development, as limited clinical data are available for these agents.<\/jats:p>","DOI":"10.1093\/cid\/civ003","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T01:26:26Z","timestamp":1421198786000},"page":"1319-1325","source":"Crossref","is-referenced-by-count":211,"title":["Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum \u03b2-Lactamase Bacteremia"],"prefix":"10.1093","volume":"60","author":[{"given":"Pranita D.","family":"Tamma","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine 1 Department of Pediatrics, Division of Infectious Diseases , , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Han","sequence":"additional","affiliation":[{"name":"University of Pennsylvania School of Medicine, Philadelphia 2 Department of Medicine, Division of Infectious Diseases ,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Rock","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine 3 Department of Epidemiology and Public Health ,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Harris","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine 3 Department of Epidemiology and Public Health ,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebbing","family":"Lautenbach","sequence":"additional","affiliation":[{"name":"University of Pennsylvania School of Medicine, Philadelphia 2 Department of Medicine, Division of Infectious Diseases ,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice J.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Johns Hopkins Hospital 4 Department of Pharmacy ,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Avdic","sequence":"additional","affiliation":[{"name":"Johns Hopkins Hospital 4 Department of Pharmacy ,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine 5 Department of Medicine, Division of Infectious Diseases , , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,1,13]]},"reference":[{"key":"2024111411394159500_CIV003C1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024111411394159500_CIV003C2","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1128\/AAC.49.7.2598-2605.2005","article-title":"Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases","volume":"49","author":"Endimiani","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411394159500_CIV003C3","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1128\/AAC.48.12.4574-4581.2004","article-title":"Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy","volume":"48","author":"Kang","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411394159500_CIV003C4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1086\/665715","article-title":"An outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit","volume":"33","author":"Tamma","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024111411394159500_CIV003C5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/00365540151060806","article-title":"Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia","volume":"33","author":"Menashe","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"2024111411394159500_CIV003C6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-140-1-200401060-00008","article-title":"International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections","volume":"140","author":"Paterson","year":"2004","journal-title":"Ann Intern Med"},{"key":"2024111411394159500_CIV003C7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024111411394159500_CIV003C8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.50.5.1715-1720.2006","article-title":"Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae","volume":"50","author":"Anderson","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411394159500_CIV003C9","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/archinte.165.12.1375","article-title":"Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: variability by site of infection","volume":"165","author":"Hyle","year":"2005","journal-title":"Arch Intern Med"},{"key":"2024111411394159500_CIV003C10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/cir793","article-title":"Can we really use \u03b2-lactam\/\u03b2-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum \u03b2-lactamase-producing bacteria?","volume":"54","author":"Perez","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024111411394159500_CIV003C11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024111411394159500_CIV003C12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/cid\/ciu069","article-title":"The treatment of multi-drug resistant gram-negative infections in children","volume":"58","author":"Hsu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024111411394159500_CIV003C13","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2024111411394159500_CIV003C14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/598244","article-title":"Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns","volume":"30","author":"Hussein","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024111411394159500_CIV003C15","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1086\/592412","article-title":"Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies","volume":"29","author":"Patel","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024111411394159500_CIV003C16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2024111411394159500_CIV003C17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1086\/666632","article-title":"Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests","volume":"33","author":"Marchaim","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024111411394159500_CIV003C18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jinf.2011.02.009","article-title":"Antimicrobial susceptibility profiles of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria","volume":"62","author":"Chen","year":"2011","journal-title":"J Infect"},{"key":"2024111411394159500_CIV003C19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.diagmicrobio.2012.05.024","article-title":"Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009\u20132010","volume":"74","author":"Hoban","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024111411394159500_CIV003C20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/cid\/cit395","article-title":"The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae","volume":"57","author":"Tamma","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024111411394159500_CIV003C21","article-title":"Performance standards for antimicrobial susceptibility testing; approved standard. Twenty-fourth informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2014"},{"key":"2024111411394159500_CIV003C22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/319757","article-title":"Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes","volume":"32","author":"Lautenbach","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2024111411394159500_CIV003C23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/668443","article-title":"Risk factors for gastrointestinal tract colonization with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella species in hospitalized patients","volume":"33","author":"Han","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024111411394159500_CIV003C24","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3201\/eid1308.070071","article-title":"Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission","volume":"13","author":"Harris","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"2024111411394159500_CIV003C25","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411394159500_CIV003C26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1469-0691.2009.02893.x","article-title":"Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates","volume":"16","author":"Lopez-Cerero","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2024111411394159500_CIV003C27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"Beta-lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024111411394159500_CIV003C28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/106002809502900510","article-title":"Piperacillin\/tazobactam: a new beta-lactam\/beta-lactamase inhibitor combination","volume":"29","author":"Schoonover","year":"1995","journal-title":"Ann Pharmacother"},{"key":"2024111411394159500_CIV003C29","article-title":"Zosyn (piperacillin and tazobactam for injection).","author":"US Food and Drug Administration"},{"key":"2024111411394159500_CIV003C30","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/cid\/cit017","article-title":"Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam","volume":"56","author":"Dudley","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024111411394159500_CIV003C31","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1128\/AAC.01808-09","article-title":"Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007\u20132008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"54","author":"Hoban","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/9\/1319\/1129246\/civ003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/60\/9\/1319\/1129246\/civ003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:46:59Z","timestamp":1731584819000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/60\/9\/1319\/404190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,13]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,1,13]]},"published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ003","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,5,1]]},"published":{"date-parts":[[2015,1,13]]}}}